drugset / Trial / NCT07711002
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received docetaxel chemotherapy or a prostate-specific membrane antigen (PSMA)-directed lutetium-177 radioligand therapy with no evidence of disease progression and PSA ≥ 0.2 ng/mL.
Timeline
- Start
- 2026-10-01
- Primary completion
- 2031-06-17
- Completion
- 2033-06-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Saruparib | Small molecule | 60 mg | Oral |
| Background | Abiraterone acetate | Small molecule | — | — |
| Background | Darolutamide | Other / unclassified | — | — |
| Background | Enzalutamide | Other / unclassified | — | — |